David Laharie

机构：Université de Bordeaux, Inserm, Centre Hospitalier Universitaire de Bordeaux, Hôpital Cardiologique du Haut-Lévêque · ORCID：0000-0002-4753-6676

发表论文 603 篇 · 总被引 15292 次 · h-index 67

代表论文

• Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 8)
• One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study (2026 · Alimentary Pharmacology & Therapeutics · 被引 6)
• Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn’s Disease: Results From the VIVID-2 Open-Label Extension Trial (2026 · Clinical Gastroenterology and Hepatology · 被引 3)
• Association between physical activity with disease activity and functional disability in patients with inflammatory bowel disease (2026 · Digestive and Liver Disease · 被引 3)
• DOP007 Ustekinumab for Fistulizing Perianal Crohn’s Disease: week-48 results from the USTAP Randomized Placebo-ControlledTrial (2026 · Journal of Crohn s and Colitis · 被引 2)
• OP21 Evolving risk of colorectal neoplasia in IBD in the biologic era: analysis of the I-CARE European observational prospective cohort. (2026 · Journal of Crohn s and Colitis · 被引 2)